Evidence map›Paper›PMID 29228144›Full record

Trial reportClinical infectious diseases : an official publication of the Infectious Diseases Society of America2018

Randomized Controlled Trial of Daily Text Messages to Support Adherence to Preexposure Prophylaxis in Individuals at Risk for Human Immunodeficiency Virus: The TAPIR Study.

David J Moore, Sonia Jain, Michael P Dubé, Eric S Daar, Xiaoying Sun, Jason Young, Katya Corado, Eric Ellorin, Joel Milam, Deborah Collins and 5 more

Registry-linked trialOpen access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01761643 (CCTG 595), which is not on this map. Cited by 71 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
71citing papers in PubMed, 8 pooled it
5.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01761643 phase4completednot on this map

CCTG 595: A Multicenter, Randomized Study of Text Messaging to Improve Adherence to PrEP in Risky MSM

TypeinterventionalSponsorUniversity of California, San DiegoRan2012 to 2018Enrolled398ConditionsPatient Adherence, HIV SeronegativityArmsSoC + iTab
3 · Its place in the literature

Who cites it

71 citing papers in PubMed, 8 syntheses or guidelines pooled it, 102 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

11 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 1 country.

David J MooreUniversity of California, San Diego.
Sonia JainUniversity of California, San Diego.
Michael P DubéUniversity of Southern California, Keck School of Medicine, Los Angeles.
Eric S DaarLos Angeles Biomedical Research Institute at Harbor-UCLA Medical Center; Long Beach, California.
Xiaoying SunUniversity of California, San Diego.
Jason YoungUniversity of California, San Diego.
Katya CoradoLos Angeles Biomedical Research Institute at Harbor-UCLA Medical Center; Long Beach, California.
Eric EllorinUniversity of California, San Diego.
Joel MilamUniversity of Southern California, Keck School of Medicine, Los Angeles.
Deborah CollinsLong Beach Department of Health and Human Services, Long Beach, California.
Jill BlumenthalUniversity of California, San Diego.
Brookie M BestUniversity of California, San Diego.
Peter AndersonUniversity of Colorado, Denver, Foster City, California.
Richard HaubrichGilead Sciences, Inc, Foster City, California.
Sheldon R MorrisUniversity of California, San Diego.
University of California, San Diego · USCalifornia State University, Long Beach · USUniversity of Southern California · USDepartment of Health and Human Services · USGilead Sciences (United States) · USUniversity of Colorado Denver · US

Funding

VirologyP30AI036214 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI David Mitchell Smith · 1994 to 2026
$78.4M
STRUCTURAL NEUROIMAGING COREP30MH062512 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DAVID J MOORE · 2001 to 2026
$50.4M
UC San Diego Clinical and Translational Research InstituteKL2TR001444 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DEPP, COLIN A. · 2015 to 2024
$15.4M
NCATS NIH HHS KL2 TR001444NIAID NIH HHS P30 AI036214NIMH NIH HHS P30 MH062512
6 · The paper itself

Abstract

Background: Adherence is critical for efficacy of tenofovir disoproxil fumarate/emtricitabine (FTC) as preexposure prophylaxis (PrEP). Methods: Between February 2013 and February 2016, 398 men who have sex with men and transgender women were randomized 1:1 to receive individualized texting for adherence building (iTAB) or standard care (SoC) for 48 weeks. The primary endpoint was dried blood spot (DBS) tenofovir diphosphate (TFV-DP) concentrations at both week 12 and the last on-drug visit of >719 fmol/punch (ie, adequate adherence). Secondary outcomes included DBS TFV-DP concentrations of >1246 fmol/punch (ie, near-perfect adherence) and plasma FTC >350 ng/mL (consistent with dosing within the past 24 hours). Results: Concentrations >719 fmol/punch of TFV-DP were found in 88.6% of participants at week 12 and 82.5% at week 48. For the primary endpoint, the study arms did not differ (72.0% in iTAB and 69.2% in SoC; P > .05). For the secondary composite endpoint of >1246 fmol/punch the iTAB arm was superior to SoC (33.5% vs 24.8%; P = .06), reaching statistical significance when adjusting for age (odds ratio, 1.56 [95% confidence interval, 1.00-2.42]; P < .05). At week 48, iTAB was superior to SoC for near-perfect adherence (51.0% vs 37.4%; P = .02). At week 12, iTAB was superior to SoC for dosing in past 24 hours by plasma FTC (47.5% vs 33.3%; P = .007), but not at weeks 24, 36, and 48 (all P > .05). Conclusions: Automated text messaging is a low-burden tool that improves durability of near-perfect PrEP adherence. Clinical Trials Registration: NCT01761643.

Indexed as

Medication AdherencePre-Exposure ProphylaxisAdenineAdultAnti-HIV AgentsFemaleHIV InfectionsHumansMaleOrganophosphatesText MessagingTransgender PersonsAdenineAnti-HIV AgentsOrganophosphatestenofovir diphosphate

Identifiers

PMID29228144
PMCPMC6248545
OpenAlexW2789942566

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.